Related Experiment Video

Updated: Feb 28, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

19.0K

Emerging Protein Targets in Triple-Negative Breast Cancer: Beyond Conventional Therapy

Andrea Previtali1, Isabella Guardamagna2, Silvia Calandra1

  • 1Department of Molecular Medicine, University of Pavia, 27100 Pavia, Italy.

Cancers
|February 27, 2026
PubMed

Insights

Triple-negative breast cancer (TNBC) is aggressive, but new targeted therapies show promise. This review covers emerging treatments like antibody-drug conjugates and pathway inhibitors to overcome resistance and improve outcomes for TNBC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Triple-negative breast cancer (TNBC) is an aggressive subtype lacking ER, PR, and HER2 expression, presenting significant therapeutic challenges.
  • Conventional treatments like chemotherapy and immunotherapy face frequent resistance and relapse, necessitating novel therapeutic strategies.
  • Advances in proteomics, structural biology, and targeted protein degradation are identifying new targets for TNBC.

Purpose of the Study:

  • To review current and emerging therapeutic strategies for TNBC.
  • To focus on targeted approaches addressing tumor heterogeneity and resistance mechanisms.
  • To provide an updated overview of the evolving TNBC therapeutic landscape.

Main Methods:

  • Summarizing recent advances in targeted therapies including immune checkpoint inhibitors, PARP inhibitors, antibody-drug conjugates, and pathway inhibitors.
  • Examining clinical trial results for various targeted agents.
  • Exploring novel targets identified through omics approaches and the role of tumor metabolism and microenvironment.
  • Outlining innovative radiotherapy strategies.

Main Results:

  • Targeted therapies, including immune checkpoint inhibitors, PARP inhibitors, Trop-2-directed antibody-drug conjugates, and pathway inhibitors, show potential in clinical trials.
  • Integrative omics approaches are identifying novel therapeutic targets.
  • Tumor metabolism and microenvironment significantly influence therapeutic efficacy.
  • Innovative radiotherapy strategies are being developed.

Conclusions:

  • The TNBC therapeutic landscape is rapidly evolving with promising targeted approaches.
  • Biomarker-driven strategies are crucial for developing next-generation treatments.
  • Addressing tumor heterogeneity and resistance mechanisms is key to improving patient outcomes.
  • Further research into novel targets, metabolism, microenvironment, and radiotherapy integration is warranted.
Keywords:
omicstargeted therapytriple-negative breast cancer

More Related Videos

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

1.0K
Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.5K
Protein Networks02:26

Protein Networks

An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
4.6K